Journals / Medical Network Klinik Bilimler ve Doktor / 2003 / Cilt: 9 - Sayı: 2

Evaluation of neural tube defects risk with the use of maternal serum alpha-fetoprotein

Maternal serum alfafetoprotein ölçümü ile nöral tüp defekti riskinin değerlendirilmesi

Pages
178–183
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results are important about the sensitivity of population in the family and society health.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To inform the population about the importance of prenatal screening tests, to spread these tests and to evaluate the anomolous pregnants in the early periods in order to take care with the families.
📊
Key Findings & Data:Material and Method: There were 7918 pregnant in the interval of 14-22 gestational week in SSK Ankara Obstetrics and Gynecology Hospital between 1/3/1996-31/3/2001.
💡
Conclusion & Impact:These results are important about the sensitivity of population in the family and society health.
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Nöral tüp defektleri · alfa-Fetoproteinler · Gebelik trimester

Abstract

Objective: To inform the population about the importance of prenatal screening tests, to spread these tests and to evaluate the anomolous pregnants in the early periods in order to take care with the families. Material and Method: There were 7918 pregnant in the interval of 14-22 gestational week in SSK Ankara Obstetrics and Gynecology Hospital between 1/3/1996-31/3/2001. Maternal serum alpha-fetoprotein levels were evaluated. The tests which were over than 2.5 MoM repeated. In the repeated values if the alpha-fetoprotein levels were still 2.5 MoM or higher and the ultrasonographic results were not diagnostic, the amniocentesis were done. Alpha-fetoprotein and acetylcolinesterase levels were analyzed in the amniotic fluid. Results: Neural tube defects were detected in thirtytwo cases. In 18 of these cases the alpha-fetoprotein levels were equal or over than 2.5 MoM (four cases of anencephaly, three cases of spina bifida, three cases of meningocele, two cases of meningomyelocele, two cases of ventriculomegaly, two cases of spina bifida+ventriculomegaly, a case of encephalocele+hydrocephaly, a case of myelocele). In 14 of these cases the alpha-fetoprotein levels were less than 2.5 MoM (10 cases of hydrocephaly, two cases of spina bifida+ventriculomegaly, a case of spina bifida, a case of ventriculomegaly). The parameters found in this study were as follows: sensitivity 56.25%, specificity 98.6%, positive predictive value 13.84%, negative predictive value 99.82%, false positive rate 1.4%. Conclusion: In the year 1996, the first year of this study, in 9 months 488 pregnants applied to have a screening test. In the year 2000, in the same period 1870 pregnants applied to have a screening test. These results are important about the sensitivity of population in the family and society health.

Özet

Amaç: Toplumumuza prenatal tarama testlerinin önemini kavratmak, bunları yaygınlaştırmak ve test sonuçlarına göre aile ile işbirliği yaparak gerekli önlemlerin alınmasını sağlamak. Gereç ve Yöntem: SSK Ankara Doğumevi ve Kadın Hastalıkları Eğitim Hastanesine 1 Mart 1996-31 Mart 2001 tarihleri arasında, 14-22. gebelik haftasında test yaptırmak üzere başvuran 7918 gebede maternal serumda alfafetoprotein değerlerine bakılmıştır. Alfafetoproteini 2.5 MoM üzerinde bulunan gebelerin testleri tekrarlanmış, tekrarlanan test sonucunda alfafetoprotein değeri 2.5 MoM ve üzerinde olan, ultrasonografinin tanımlayıcı olmadığı gebelere amniosentez yapılarak amnios mayide alfafetoprotein ve asetilkolinesteraz bakılmıştır. Bulgular: Tespit edilen 32 nöral tüp defektli gebeliğin 18'inde alfafetoprotein değeri 2.5 MoM ve üzerinde (dört anensefali, üç spina bifida, üç meningosel, iki meningomyelosel, iki ventrikülomegali, iki spina bifida+ventrikülomegali, bir ensefalosel+hidrosefali, bir myelosel) bulunurken, 14'ünde alfafetoprotein değeri 2.5 MoM altında (10 hidrosefali, iki spina bifida+ventrikülomegali, bir spina bifida, bir ventrikülomegali) bulunmuştur. Testin sensitivitesi %56.25, spesifisitesi %98.6, (+) prediktivitesi %13.84, (-) prediktivitesi %99.82, yalancı (+)'lik oranı %1.4 saptanmıştır. Sonuç: İlk olarak 1996 yılında başlattığımız bu çalışmada, dokuz ayda 488 gebe tarama testi yaptırmak amacıyla müracaat ederken, 2000 yılında aynı sürede bu sayı 1870'e çıkmıştır. Bu veriler aile ve toplum sağlığı konusunda halkımızın duyarlılığını göstermek açısından dikkat çekicidir.

🔖

Cite This Article

ACUN, C., ÇAKMAK, F. N., PETEK, E., EKER, S., KAPUAĞASI, A., AYCAN, Z., ALİEFENDİOĞLU, D., KANDEMİR, Ö., DÖLEN, İ., HABERAL, A., TOKALI, E. (2003). Evaluation of neural tube defects risk with the use of maternal serum alpha-fetoprotein. Medical Network Klinik Bilimler ve Doktor, Cilt: 9 - Sayı: 2, 178–183. https://ajindex.com/articles/278497

References (14)

  1. Denise M, Main MD, Michael T, Mennuti MD. Neural tube defects: Issues in prenatal diagnosis and counseling. J Am Coll Obstet Gynecol 1986; 67:1-15.
  2. Ronald J, Lemire.MD. Neural tube defects: State of the art/Review. JAMA 1988; 259:558-60.
  3. Brock DJ, Sutcliffe RG. Alpha-fetoprotein in the antenatal di­ agnosis of anencephaly and spina bifida. Lancet 1972; 2:197-9.
  4. Wald NJ, Bonnar J. Prenatal diagnosis of spina bifida and anencephaly by MSAFP measurement-a controlled study. Lancet 1974; 1:765-7.
  5. Van Der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070-1.
  6. Şeniz FN, Gürakan BA, Fırat MS, et al. Maternal lymphocyte subsets in the cases with neural tube defects. J Clin Lab Immunol 1993; 40:181-6.
  7. Melnick M, Myrianthopoulos NC. Studies in neural tube defects II. Pathologic findings in a prospectively collected series of anencephalics. Am J Med Genet 1987; 26:797-810. Şeniz FN. The tymic findings in stillboms with neural tube defects. Clin Genet 1992; 41:62-4.
  8. Ardinger HH, Atkin JF, Blackstone RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29:177-85. Sever LE. Looking for causes of neural tube defects; where does the environment fit in?. Enviran Health Perspec 1995; 103:165-71.
  9. Çavdar AO, Arcasoy A, Bayca T. Zinc deficiency and anencephaly in Turkey. Teratology 1980; 22:141. Karataş F, Aygün D, Gürsu F. Nöral tüp defektli bebekler ve annelerinde serum çinko ve selenyum düzeyleri. Çocuk Sağlığı ve Hastalıkları Dergisi 2001; 2:115-21.
  10. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. New Engl J Med 1999; 341:1509-19.
  11. Gibson KM, Bottiglieri. Genetic predisposition to neural tube defects. Ped Res 2000; 48:135. Boduroğlu K, Alikaşifoğlu M, Anlar B, Tunçbilek E. Associa­tion of the 677C-T mutation on the methylenetetrahydrofolate re­ductase gene in Turkish patients with neural tube defects. J Child Neurol 1999; 14:159-61.
  12. Shaw GM, Velice EM, Schaffer D. Risk of neural tube de­ fects affected pregnancies among obese women. JAMA 1996; 275:1093-6.
  13. Werleri MM, Louik C, Shapira S, Mitchell A. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996; 275:1089-92. A Eurocat working group report 7-15 years of surve'llance of congenital anomalies in Europe 1980-1994. Brussels: Scientific Institute of Public Health-Louis Pasteur 1997:50-79.
  14. Tunçbilek E, Boduroğlu K, Alikaşifoğlu M. Neural tube defects in Turkey: